Aptorum Group Ltd (APM)
NASDAQ:APM
Want to see APM full AI Analyst Report?
APM Stock Chart & Stats
$1.07
-$0.08(-4.69%)
At close: 4:00 PM EST
$1.07
-$0.08(-4.69%)
Day’s Range― - ―
52-Week Range$0.65 - $4.47
Previous CloseN/A
Volume172.64K
Average Volume (3M)113.32K
Market Cap
$6.92M
Enterprise Value$5.46M
Total Cash (Recent Filing)$874.24K
Total Debt (Recent Filing)$3.35M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Sep 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding6,346,823
10 Day Avg. Volume164,850
30 Day Avg. Volume113,319
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-4.24
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.43
Enterprise Value/Ebitda-1.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.1
Revenue Forecast (FY)$106.80M
Bulls Say, Bears Say
Bulls Say
Supportive Balance SheetImproving leverage and a sizable equity base provide a durable financial buffer for a development-stage biotech. This strengthens financing optionality, underpins R&D runway and reduces immediate refinancing risk, enabling program advancement over the next several quarters.
DiamiR Merger ProgressThe planned DiamiR merger is a structural corporate change that can expand the pipeline, create a U.S. subsidiary and broaden capital-market access. If completed, it alters the company’s asset base and financing capacity, supporting longer-term development and commercialization strategy.
Reduced Cash Burn TrendA meaningful narrowing of operating losses and lower negative cash flow across recent periods indicates improving cost discipline and operational efficiency. Sustained reduction in burn rate lengthens runway and lowers the pace of required external funding over the medium term.
Bears Say
Near-zero RevenueEffectively zero recent revenue shows the company lacks commercial products and depends on R&D outcomes and partnerships for future sales. This structural revenue gap limits internal cash generation and increases reliance on financing to sustain development programs over the coming quarters.
Persistent Negative Cash FlowSustained negative operating and free cash flows force recurring external funding needs, diluting shareholders or accumulating liabilities. This chronic cash burn is a fundamental constraint on long-term program advancement and heightens execution and financing risk.
Nasdaq Minimum Bid DeficiencyA documented listing deficiency raises delisting risk and may prompt a reverse split or other measures that can dilute or disrupt investor base. Listing pressure can distract management, limit access to equity financing and materially affect long-term capital strategy.
Aptorum Group News
APM FAQ
What was Aptorum Group Ltd’s price range in the past 12 months?
Aptorum Group Ltd lowest stock price was $0.65 and its highest was $4.47 in the past 12 months.
What is Aptorum Group Ltd’s market cap?
Aptorum Group Ltd’s market cap is $6.92M.
When is Aptorum Group Ltd’s upcoming earnings report date?
Aptorum Group Ltd’s upcoming earnings report date is Sep 15, 2026 which is in 113 days.
How were Aptorum Group Ltd’s earnings last quarter?
Currently, no data Available
Is Aptorum Group Ltd overvalued?
According to Wall Street analysts Aptorum Group Ltd’s price is currently Overvalued.
Does Aptorum Group Ltd pay dividends?
Aptorum Group Ltd does not currently pay dividends.
What is Aptorum Group Ltd’s EPS estimate?
Aptorum Group Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptorum Group Ltd have?
Aptorum Group Ltd has 6,346,823 shares outstanding.
What happened to Aptorum Group Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aptorum Group Ltd?
Currently, no hedge funds are holding shares in APM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptorum Group Ltd
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.22% Other Institutional Investors
99.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---